Cloudways Demonstrates Growth Ambitions with Customer Momentum, New Features, and Key Executive Hires
Cloudways (cloudways.com), the leading cloud hosting provider focused on simplicity, flexibility, and performance, announces significant customer momentum ahead of their presence at WordCamp Europe. Cloudways’ announcements at WordCamp Europe include SafeUpdates (in beta), new automations that manage WordPress updates at scale, and partnership with Astra Pro, a collaboration allowing users to build websites faster and easier than ever before.
Cloudways supports over 70k customers and 500K+ websites and was recently rated by G2 as the best cloud hosting company for SMBs with a rating of 4.8 out of 5. Additionally, Cloudways has strengthened its executive team with the hire of ex-Microsoft executive Paul Haverstock as VP of Engineering, Bluehost executive Suhaib Zaheer as COO, and AWS executive Tom Erskine as CMO. Cloudways has significantly grown in size to more than 280 employees, with its global mindset reflected in an employee base coming from 20+ countries.
Cloudways focuses on giving agencies, SMBs, e-commerce providers, and individuals a hassle-free, premium experience to help them grow their business with both peace of mind and improved productivity. The Cloudways platform features >99.9% uptime, fast page load times, pro-active app monitoring, dedicated workflows, leading security with add-ons from Cloudflare, and 24/7 premium support. Great value and flexibility are also key platform features with pay-as-you-go plans offered from cloud providers including AWS, Google Cloud, Linode, Vultur, and Digital Ocean and a choice of 65+ Data Center locations.
SafeUpdates, which is being launched in beta, is Cloudways’ newest feature and will enable agencies and developers to update their WordPress websites both automatically and on demand. The workflow secures a backup, performs advanced visual regression testing and performance checks on both staging and live, and then deploys selected updates to production or automatically rolls back the changes in case of any issues. SafeUpdates allows agencies and developers to automate their work, focus on their business, and upsell maintenance services with confidence.
Cloudways’ partnership with Astra Pro is part of a series of collaborations the company has made in recent months to enhance WordPress simplicity and ensure maximum performance and security on its platform. Cloudways has worked closely with Cloudflare, OceanWP, Divi, and OCP among others to offer a seamless, no-code digital experience for agencies and developers to build and secure WordPress websites.
“Cloudways is both growing as a company and building significant momentum in the cloud hosting industry,” said Aaqib Gadit, Co-Founder and CEO of Cloudways. “The recent addition of Suhaib, Tom, and Paul to our leadership team shows the growth plans and ambition we have for Cloudways. At Cloudways, we are deeply focused on being a trusted partner to our customers and are continually innovating to save them both time and money while delivering a great user experience.”
To learn more, visit Cloudways’ booth at WordCamp Europe at https://www.cloudways.com/en/wordcamp-europe.php
About Cloudways:
Founded in 2012, Cloudways is an intuitive, one-click managed cloud hosting platform that hosts over 50,000 servers globally. G2’s Best Managed Hosting Provider for 2021, the platform lets users host WordPress and WooCommerce websites on top of a variety of cloud-hosting providers, including Google Cloud, Amazon Web Services, DigitalOcean, Vultr, and Linode. The platform features a web app management function that easily launches cloud servers for the deployment of WordPress, Magento, and PHP. Visit the company website at https://www.cloudways.com/en/about_us.php
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005120/en/
Contact information
Cloudways Media Contact:
Lauren Perry
SlicedBrand for Cloudways
lauren@slicedbrand.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom